Showing results (111-120 of 162) with videos related to

Sort By:
Pageof 17
Plos One|March 17, 2016
A Proof of Concept, Phase II Randomized European Trial, on the Efficacy of ALF-5755, a Novel Extracellular Matrix-Targeted Antioxidant in Patients with Acute Liver DiseasesBertrand Nalpas, Philippe Ichaï, Laure Jamot, et al.
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|September 26, 2020
Alcohol Consumption the Day of Liver Transplantation for Alcohol-Associated Liver Disease Does Not Affect Long-Term Survival: A Case-Control StudyJosé Ursic-Bedoya, Jérôme Dumortier, Romain Altwegg, et al.
Digestive Diseases and Sciences|January 29, 2016
Effectiveness and Safety of Tenofovir Disoproxil Fumarate in Chronic Hepatitis B: A 3-Year, Prospective, Real-World Study in FrancePatrick Marcellin, Fabien Zoulim, Christophe Hézode, et al.
Gastroenterology|September 20, 2011
Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infectionStefan Zeuzem, Tarik Asselah, Peter Angus, et al.
JHEP Reports : Innovation in Hepatology|February 9, 2026
Plasma exchange as potential treatment of severe immune checkpoint inhibitor-induced hepatitisLucy Meunier, Clement Monet, Antonio Saviano, et al.
Antiviral Therapy|April 6, 2013
Faldaprevir (BI 201335), deleobuvir (BI 207127) and ribavirin oral therapy for treatment-naive HCV genotype 1: SOUND-C1 final resultsStefan Zeuzem, Tarik Asselah, Peter Angus, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|May 9, 2020
Phase 3, Multicenter Open-Label study to investigate the efficacy of elbasvir and grazoprevir fixed-dose combination for 8 weeks in treatment-naïve, HCV GT1b-infected patients, with non-severe fibrosisArmand Abergel, Tarik Asselah, Arianne Mallat, et al.
Digestive Diseases and Sciences|April 19, 2020
Evolution of Hepatitis C Virus Treatment During the Era of Sofosbuvir-Based Therapies: A Real-World Experience in FranceDenis Ouzan, Dominique Larrey, Dominique Guyader, et al.
Clinical Pharmacology and Therapeutics|November 2, 2020
Genetic Risk Factors in Drug-Induced Liver Injury Due to Isoniazid-Containing Antituberculosis Drug RegimensPaola Nicoletti, Harshad Devarbhavi, Ashish Goel, et al.
Health Science Reports|April 3, 2019
Ombitasvir/paritaprevir/ritonavir plus ribavirin for 24 weeks in patients with HCV GT4 and compensated cirrhosis (AGATE-I Part II)Tarik Asselah, Negar Niki Alami, Christophe Moreno, et al.
Pageof 17